Details of the Drug Combination

General Information of Drug Combination (ID: DC6D8L5)

Drug Combination Name
Lactulose Rifaximin
Indication
Disease Entry Status REF
Hepatic Encephalopathy Phase 4 [1]
Component Drugs Lactulose   DMSAOWQ Rifaximin   DMW1TV2
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Lactulose
Disease Entry ICD 11 Status REF
Constipation DD91.1 Approved [2]
Hepatic encephalopathy DB99.5 Approved [3]
Ornithine transcarbamylase deficiency 5C50.AY Approved [3]
Lactulose Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-galactosidase (bgaB) DEIEY19 BGAL_CROS8 Metabolism [6]
Beta-glucosidase (bglA) DE235K6 Q3Y0M8_ENTFD Metabolism [6]
Glycosyl hydrolase (glyH) DEPB9C2 A0A379KQ43_PSEPU Metabolism [6]
------------------------------------------------------------------------------------
Indication(s) of Rifaximin
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [4]
Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [5]
Hepatic encephalopathy DB99.5 Approved [5]
Rifaximin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Rifaximin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Rifaximin Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [9]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [9]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Expression [10]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Hepatic Encephalopathy DCDAGVV N. A. Phase 1 [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01842581) The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Lactulose FDA Label
4 ClinicalTrials.gov (NCT01654939) Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease. U.S. National Institutes of Health.
5 Rifaximin FDA Label
6 In vitro fermentation of lactulose by human gut bacteria. J Agric Food Chem. 2014 Nov 12;62(45):10970-7.
7 Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability. AAPS J. 2017 May;19(3):806-813.
8 Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth. Ann Pharmacother. 2011 May;45(5):e25.
9 Solomonsterols A and B from Theonella swinhoeiThe first example of C-24 and C-23 sulfated sterols from a marine source endowed with a PXR agonistic activity. J Med Chem. 2011 Jan 13;54(1):401-5.
10 Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity. J Med Chem. 2011 Jul 14;54(13):4590-9. doi: 10.1021/jm200241s. Epub 2011 Jun 3.
11 ClinicalTrials.gov (NCT00364689) RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial